However, the increase in BIM levels as the driving force of the synergy may be a more possible hypothesis since not every CLL sample treated with both drugs ex vivo presented with altered anti-apoptotic BCL2 protein levels [62]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.